Methotrexate extended-release - Pacira BioSciences
Alternative Names: DepoMethotrexateLatest Information Update: 21 Jan 2022
At a glance
- Originator Pacira Pharmaceuticals
- Developer Pacira BioSciences
- Class Abortifacients; Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Eye disorder therapies; Glutamates; Heart failure therapies; Pterins; Small molecules
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 09 Apr 2019 Pacira Pharmaceuticals is now called Pacira BioSciences
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral, Controlled release)
- 27 Mar 2012 Preclinical development is ongoing in USA